ArticlePharmaceuticals (Basel, Switzerland)2025

Hydrazonylthiazole Derivatives as Dual EGFR and ALR2 Inhibitors: Design, Synthesis, and Comprehensive In Vitro and In Silico Evaluation for Potential Anticancer Activity.

Belgin Sever et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.